Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States; Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV-IPN), Ciudad de México, Mexico
Bin Xu
Department of Biomedical Engineering, University of Minnesota, Minneapolis, United States
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States; Stem Cell Institute, University of Minnesota, Minneapolis, United States
Hyunkee Kim
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States
Jeanne Lainé
Département de Physiologie, Sorbonne Universités, Faculté de Médecine site Pitié-Salpêtrière, Paris, France
James Kiley
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States
Holly Mckee
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States
Fabrizio Rinaldi
Stem Cell Department, Bio-Techne, Minneapolis, United States
Joy Aho
Stem Cell Department, Bio-Techne, Minneapolis, United States
Nacira Tabti
Département de Physiologie, Sorbonne Universités, Faculté de Médecine site Pitié-Salpêtrière, Paris, France
Wei Shen
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States; Department of Biomedical Engineering, University of Minnesota, Minneapolis, United States; Stem Cell Institute, University of Minnesota, Minneapolis, United States
Lillehei Heart Institute, Department of Medicine, University of Minnesota, Minneapolis, United States; Stem Cell Institute, University of Minnesota, Minneapolis, United States
Targeted differentiation of pluripotent stem (PS) cells into myotubes enables in vitro disease modeling of skeletal muscle diseases. Although various protocols achieve myogenic differentiation in vitro, resulting myotubes typically display an embryonic identity. This is a major hurdle for accurately recapitulating disease phenotypes in vitro, as disease commonly manifests at later stages of development. To address this problem, we identified four factors from a small molecule screen whose combinatorial treatment resulted in myotubes with enhanced maturation, as shown by the expression profile of myosin heavy chain isoforms, as well as the upregulation of genes related with muscle contractile function. These molecular changes were confirmed by global chromatin accessibility and transcriptome studies. Importantly, we also observed this maturation in three-dimensional muscle constructs, which displayed improved in vitro contractile force generation in response to electrical stimulus. Thus, we established a model for in vitro muscle maturation from PS cells.